Jie Ni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6627763/publications.pdf

Version: 2024-02-01

49 papers	2,817 citations	236925 25 h-index	289244 40 g-index
49 all docs	49 docs citations	49 times ranked	4689 citing authors

#	Article	IF	Citations
1	Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?. Cancer Letters, 2021, 497, 100-111.	7.2	107
2	Endoplasmic Reticulum Stress and Tumor Microenvironment in Bladder Cancer: The Missing Link. Frontiers in Cell and Developmental Biology, 2021, 9, 683940.	3.7	26
3	Activation of the eIF2Î±/ATF4 axis drives triple-negative breast cancer radioresistance by promoting glutathione biosynthesis. Redox Biology, 2021, 43, 101993.	9.0	30
4	Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance. Journal of the National Cancer Center, 2021, 1, 75-87.	7.4	20
5	THOC2 and THOC5 Regulate Stemness and Radioresistance in Tripleâ€Negative Breast Cancer. Advanced Science, 2021, 8, e2102658.	11.2	17
6	Exosomal microRNAs as liquid biopsy biomarkers in prostate cancer. Critical Reviews in Oncology/Hematology, 2020, 145, 102860.	4.4	73
7	Exosomes and breast cancer drug resistance. Cell Death and Disease, 2020, 11, 987.	6.3	103
8	A Clinician's Guide to Cancer-Derived Exosomes: Immune Interactions and Therapeutic Implications. Frontiers in Immunology, 2020, 11, 1612.	4.8	21
9	CD44 variant 6 is associated with prostate cancer growth and chemo-/radiotherapy response in vivo. Experimental Cell Research, 2020, 388, 111850.	2.6	7
10	Quality Assessment and Comparison of Plasma-Derived Extracellular Vesicles Separated by Three Commercial Kits for Prostate Cancer Diagnosis . International Journal of Nanomedicine, 2020, Volume 15, 10241-10256.	6.7	16
11	Extracellular vesicles: the next generation of biomarkers for liquid biopsy-based prostate cancer diagnosis. Theranostics, 2020, 10, 2309-2326.	10.0	124
12	Abstract 6163: Integrated stress response contributes to triple negative breast cancer radioresistance by regulating glutathione biosynthesis. , 2020, , .		0
13	CHTOP in Chemoresistant Epithelial Ovarian Cancer: A Novel and Potential Therapeutic Target. Frontiers in Oncology, 2019, 9, 557.	2.8	11
14	Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression. BMC Cancer, 2019, 19, 618.	2.6	153
15	Cancer stem cells in prostate cancer radioresistance. Cancer Letters, 2019, 465, 94-104.	7.2	49
16	Exosomes in Cancer Radioresistance. Frontiers in Oncology, 2019, 9, 869.	2.8	60
17	In Vivo 3D MRI Measurement of Tumour Volume in an Orthotopic Mouse Model of Prostate Cancer. Cancer Control, 2019, 26, 107327481984659.	1.8	8
18	Liquid biopsy in ovarian cancer: recent advances in circulating extracellular vesicle detection for early diagnosis and monitoring progression. Theranostics, 2019, 9, 4130-4140.	10.0	59

#	Article	IF	Citations
19	Abstract 4754: CHTOP is a novel therapeutic target for chemoresistant epithelial ovarian cancer therapy. , 2019, , .		0
20	Abstract 4754: CHTOP is a novel therapeutic target for chemoresistant epithelial ovarian cancer therapy. , 2019, , .		1
21	Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy/radiotherapy response in vivo. BMC Cancer, 2018, 18, 1092.	2.6	29
22	Cancer stem cell in breast cancer therapeutic resistance. Cancer Treatment Reviews, 2018, 69, 152-163.	7.7	197
23	Abstract 1999: Study of CD44 variant 6 (CD44v6) in prostate cancer chemo-/radio resistance in vivo. , 2018, , .		1
24	Identification of protein biomarkers and signaling pathways associated with prostate cancer radioresistance using label-free LC-MS/MS proteomic approach. Scientific Reports, 2017, 7, 41834.	3.3	59
25	Enhanced osteointegration of tantalum-modified titanium implants with micro/nano-topography. RSC Advances, 2017, 7, 46472-46479.	3.6	11
26	Urinary biomarkers in prostate cancer detection and monitoring progression. Critical Reviews in Oncology/Hematology, 2017, 118, 15-26.	4.4	64
27	Studying CD44 variant 6 (CD44v6) in prostate cancer progression and chemo-/radio-resistance using in vivo mouse models. Annals of Oncology, 2017, 28, x78-x79.	1.2	0
28	Targeting MicroRNAs in Prostate Cancer Radiotherapy. Theranostics, 2017, 7, 3243-3259.	10.0	64
29	Abstract 2833: Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer progression and chemo-/radio-resistanceinvitroandin vivo. , 2017, , .		0
30	Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer. Oncotarget, 2016, 7, 55771-55788.	1.8	85
31	Clinical Evaluation and Patient Satisfaction of Single Zirconiaâ€Based and Highâ€Noble Alloy Porcelainâ€Fusedâ€toâ€Metal Crowns in the Esthetic Area: A Retrospective Cohort Study. Journal of Prosthodontics, 2016, 25, 526-530.	3.7	14
32	Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy. Expert Review of Proteomics, 2016, 13, 905-915.	3.0	8
33	Monitoring Prostate Tumor Growth in an Orthotopic Mouse Model Using Three-Dimensional Ultrasound Imaging Technique. Translational Oncology, 2016, 9, 41-45.	3.7	18
34	Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy. Oncotarget, 2016, 7, 74269-74285.	1.8	24
35	Cancer stem cells and signaling pathways in radioresistance. Oncotarget, 2016, 7, 11002-11017.	1.8	92
36	Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance. Critical Reviews in Oncology/Hematology, 2015, 96, 507-517.	4.4	154

#	Article	IF	Citations
37	Abstract 2001: Identification of lactate dehydrogenase A (LDHA) as a potential therapeutic target for prostate cancer radiotherapy. , 2015, , .		0
38	CD44 variant 6 is associated with prostate cancer metastasis and chemoâ€/radioresistance. Prostate, 2014, 74, 602-617.	2.3	126
39	PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death and Disease, 2014, 5, e1437-e1437.	6.3	256
40	Cancer Stem Cells in Prostate Cancer Chemoresistance. Current Cancer Drug Targets, 2014, 14, 225-240.	1.6	48
41	Abstract 4005: CD44 isoform variant 6 is associated with prostate cancer progression, metastasis and chemo-/radio-resistance via PI3K/Akt/mTOR and Wnt/Î²-catenin signaling pathwaysin vitro. , 2014, , .		0
42	Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. International Journal of Biochemistry and Cell Biology, 2013, 45, 2736-2748.	2.8	155
43	Acquisition of epithelialâ€“mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death and Disease, 2013, 4, e875-e875.	6.3	321
44	The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression. Cancer and Metastasis Reviews, 2013, 32, 535-551.	5.9	71
45	Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro. Cancer Letters, 2013, 329, 17-26.	7.2	29
46	The CD44 Isoforms in Prostate Cancer Metastasis and Progression. World Journal of Cancer Research, 2013, 1, 3-14.	0.2	3
47	Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells. PLoS ONE, 2013, 8, e74253.	2.5	35
48	Abstract A283: PI3K/Akt/mTOR dual inhibitors have an advantage over single inhibitors in overcoming prostate cancer radioresistance.. , 2013, , .		0
49	Role of the EpCAM (CD326) in prostate cancer metastasis and progression. Cancer and Metastasis Reviews, 2012, 31, 779-791.	5.9	68